Lew Bender Email and Phone Number

Intensity is developing proprietary intratumoral immunotherapy products that both directly kill injected solid tumors and induce immune system recognition of cancer cells throughout the body to address the three challenges of cancer treatment: local, regional, and metastatic disease. Mr. Bender developed the technology and founded the Company in 2012 with the objective of dramatically improving the outcomes for cancer patients. Our novel approach treats both the macro and the micro aspects of cancer. When injected intratumorally (dosed locally), our products have high tumor dispersion and cell penetration properties. These injected products directly kill the tumor cells. This localized cell death results in the creation of antigenic sites that stimulate the adaptive immune system (act globally). The elicited immune response helps to destroy or regress the injected tumor, while also eliminating secondary tumors and micrometastases. The new drug in clinical trials under both a U.S. FDA Investigational New Drug (IND) and a Health Canada-approved clinical trial application (CTA). Since 2017, more than 70 patients have been treated. The US PTO granted the Company patents 9,351,997 in 2016, 9,636,406 in 2017 and 10,. There are over 45 issued patients Mr. Bender successfully completed a series A, B and C financings that raised over $30,000,000. Visit www.intensitytherapeutics.com

Interleukin Genetics, Inc. a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. The Company markets a line of personalized genetic tests to improve health and wellness under the Inherent Health® brand for Weight Management, Bone Health, Heart Health, and Nutritional Needs. In additional, the Company has PST a genetic test to predict risk of periodontal disease. Under Lew Bender's leadership, the Company developed the Inherent Health brand, partnered with the insurance firm Delta Dental of Michigan and successfully completed a 5400 patient study demonstrating the utility of the PST test.

Emisphere is a drug delivery company specializing in oral delivery of non orally available compounds. Lew Bender held positions as Chief Technology Officer, interim CEO, Senior Vice President of Business Development, Vice President of Manufacturing. He was the lead negotiator for several complex business agreements that were executed including out-licensing partnerships, in-licensing agreements, international joint venture agreements, asset acquisitions and stock purchases agreements with major pharmaceutical and biotechnology companies and was involved in raising capital on a number of occasions.

Led the Company during a transition period. Established improved communications with investors, analysts and BOD.